CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CytoMed (NASDAQ: GDTC) stock is down 33% over the last 24 hours. GDTC stock fell in a mixture of real trading time, the aftermarket and now this morning. The reason for the decline is simply that it ...

CytoMed (NASDAQ: GDTC) stock is up 100%. The rise in GDTC stock seems to be coming from the award of a patent. This is a very silly idea, quite ridiculous. Of course, it's just great for those who ...

Short interest in CytoMed Therapeutics Ltd (NASDAQ:GDTC) decreased during the last reporting period, falling from 65.20K to 56.79K. This put 1.73% of the company's publicly available shares short.

View CytoMed Therapeutics Limited GDTC stock quote prices, financial information, real-time forecasts, and company news from CNN.

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...